Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Cymabay Therapeutics (CBAY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 209,875
  • Shares Outstanding, K 28,750
  • Annual Sales, $ 0 K
  • Annual Income, $ -26,670 K
  • 36-Month Beta 2.04
  • Price/Sales 43.82
  • Price/Cash Flow N/A
  • Price/Book 22.98

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.00 +55.00%
on 06/27/17
7.94 -2.39%
on 07/21/17
+2.64 (+51.66%)
since 06/21/17
3-Month
3.16 +145.25%
on 04/27/17
7.94 -2.39%
on 07/21/17
+4.17 (+116.48%)
since 04/21/17
52-Week
1.15 +573.91%
on 11/09/16
7.94 -2.39%
on 07/21/17
+6.08 (+364.07%)
since 07/21/16

Most Recent Stories

More News
Cymabay Therapeutics (CBAY) Catches Eye: Stock Gains 6.2%

Cymabay Therapeutics, Inc. (CBAY) moved big last session, as its shares rose over 6% on the day.

CBAY : 7.75 (+6.16%)
ANTM : 190.65 (-0.02%)
CymaBay Announces Proposed Public Offering of Common Stock

CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it intends...

CBAY : 7.75 (+6.16%)
CymaBay Announces Positive Interim Results from Its Ongoing Low-Dose Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis

-- Strong reduction in alkaline phosphatase of 39% (5 mg) and 45% (10 mg) at week 12

CBAY : 7.75 (+6.16%)
Implied Volatility Surging for Cymabay Therapeutics (CBAY) Stock Options

Investors need to pay close attention to Cymabay Therapeutics (CBAY) stock based on the movements in the options market lately.

CBAY : 7.75 (+6.16%)
New Analyst Coverage Make These 5 Stocks Worth a Bet

Most investors depend on analysts' research before taking decisions as they fear that lack of information might trigger inefficiencies. Here, analysts play a vital intermediary role with their extensive...

KIN : 7.60 (-3.80%)
CBAY : 7.75 (+6.16%)
DIOD : 26.36 (-1.79%)
INSW : 22.73 (+0.35%)
CUTR : 26.90 (+1.13%)
CymaBay Announces the Appointment of Klara Dickinson as Senior Vice President, Regulatory Affairs and Quality Assurance and the Promotion of Daniel Menold to Vice President, Finance

CymaBay Therapeutics, Inc. (Nasdaq:CBAY), today announced the appointment of Klara Dickinson as Senior Vice President, Regulatory Affairs and Quality Assurance and the promotion of Daniel Menold to Vice...

CBAY : 7.75 (+6.16%)
CymaBay Reports First Quarter 2017 Financial Results and Provides Corporate Update

CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases with high unmet medical need, today announced financial...

CBAY : 7.75 (+6.16%)
How These Biotech Stocks are Faring? -- Cymabay Therapeutics, Benitec Biopharma, Sage Therapeutics, and Catalyst Biosciences

On Tuesday, April 25, 2017, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Eight out of nine sectors ended Tuesday's trading session in bullish...

BNTC : 2.31 (unch)
CBAY : 7.75 (+6.16%)
SAGE : 83.61 (+2.70%)
CBIO : 4.28 (+1.42%)
BNIKF : 0.0980 (unch)
CymaBay to Present Data from its Phase 2 Proof-of-Concept Study of Seladelpar in Patients With Primary Biliary Cholangitis at the EASL Liver Meeting 2017

CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for specialty and orphan diseases with high unmet medical need, today announced that...

CBAY : 7.75 (+6.16%)
CymaBay Therapeutics to Present at Two Investor Conferences in April

CymaBay Therapeutics, Inc. (NASDAQ:CBAY), a clinical-stage biopharmaceutical company developing therapies for specialty and orphan diseases with high unmet medical need, today announced that management...

CBAY : 7.75 (+6.16%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy and ranks in the Top 1% of all short term signal directions.

Longer term, the trend strength is in the Top 1%. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

CymaBay Therapeutics Inc. is a biopharmaceutical company. It is focused on the development and commercialization of proprietary new medicines for important human diseases. The Company's lead product candidate, arhalofenate, is being developed for the treatment of gout. CymaBay Therapeutics Inc. is based...

See More

Support & Resistance

2nd Resistance Point 8.40
1st Resistance Point 8.07
Last Price 7.75
1st Support Level 7.29
2nd Support Level 6.84

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.